U.S., May 10 -- ClinicalTrials.gov registry received information related to the study (NCT06963346) titled 'Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents' on April 29.
Brief Summary: In this study, we aim to evaluate the safety and efficacy of neoadjuvant combination using intravesical romidepsin and durvalumab in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC).
Study Start Date: April 23
Study Type: INTERVENTIONAL
Condition:
Bladder Cancer
Intervention:
DRUG: Romidepsin
Administered as intravesical treatment.
DRUG: Durvalumab
Administered as intravenous treatment.
Recruitment Status: RECRUITING
Sponsor: H. Lee Moffitt Cancer Center and Research Institute...